Patient characteristics
| Patient ID . | Age at diagnosis, y . | Age at treatment, y . | Sex . | Indication for treatment . | Prior therapies . | Genetic abnormalities/IgVH mutation status . | WBC count, × 103/μL . | ALC, × 103/μL . | Hgb level, g/dL . | PLT count, ×103/μL . |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | 44 | 51 | M | Bulky LAD | FCR, PCRM | del11q | 200.6 | 196.6 | 7.1 | 26 |
| CLL-2 | 66 | 72 | M | Bulky LAD | FR, RCVP, PCRM | Unmutated IgVH | 4.2 | 3.4 | 9.9 | 60 |
| CLL-3 | 62 | 73 | F | Bulky LAD | Chlorambucil, PCR, PCRM | Normal karyotype | 136.4 | 132.3 | 8.9 | 100 |
| CLL-4 | 63 | 69 | M | Bulky LAD | R, PCRM | del11q | 187.1 | 174 | 9.9 | 189 |
| CLL-5 | 65 | 68 | M | Bulky LAD | PCR | del11q, trisomy 12 | 76.3 | 66.4 | 10 | 162 |
| CLL-6 | 56 | 68 | M | Bulky LAD | RCVP, PCR, Bendamustine | del11q, inv1, unmutated IgVH | 97.1 | 92.2 | 8.9 | 174 |
| CLL-7 | 52 | 62 | M | Bulky LAD | CVP, RC, PCR, PCRM | del17p, unmutated IgVH | 1.9 | 1 | 10 | 61 |
| CLL-8 | 58 | 61 | M | Bulky LAD | RCVP, Alemtuzumab | del17p, monosomy 14, monosomy 15 | 5.4 | 3.3 | 11.6 | 41 |
| ALL-1 | 66 | 67 | M | Relapsed disease | C, Mitoxantrone, vincristine, etoposide | Normal karyotype | 2.9 | 0.7 | 8.6 | 126 |
| ALL-2 | 45 | 48 | F | Relapsed disease | HyperCVAD, mitoxantrone, cytarabine, vincristine | Normal karyotype | * | * | * | * |
| Patient ID . | Age at diagnosis, y . | Age at treatment, y . | Sex . | Indication for treatment . | Prior therapies . | Genetic abnormalities/IgVH mutation status . | WBC count, × 103/μL . | ALC, × 103/μL . | Hgb level, g/dL . | PLT count, ×103/μL . |
|---|---|---|---|---|---|---|---|---|---|---|
| CLL-1 | 44 | 51 | M | Bulky LAD | FCR, PCRM | del11q | 200.6 | 196.6 | 7.1 | 26 |
| CLL-2 | 66 | 72 | M | Bulky LAD | FR, RCVP, PCRM | Unmutated IgVH | 4.2 | 3.4 | 9.9 | 60 |
| CLL-3 | 62 | 73 | F | Bulky LAD | Chlorambucil, PCR, PCRM | Normal karyotype | 136.4 | 132.3 | 8.9 | 100 |
| CLL-4 | 63 | 69 | M | Bulky LAD | R, PCRM | del11q | 187.1 | 174 | 9.9 | 189 |
| CLL-5 | 65 | 68 | M | Bulky LAD | PCR | del11q, trisomy 12 | 76.3 | 66.4 | 10 | 162 |
| CLL-6 | 56 | 68 | M | Bulky LAD | RCVP, PCR, Bendamustine | del11q, inv1, unmutated IgVH | 97.1 | 92.2 | 8.9 | 174 |
| CLL-7 | 52 | 62 | M | Bulky LAD | CVP, RC, PCR, PCRM | del17p, unmutated IgVH | 1.9 | 1 | 10 | 61 |
| CLL-8 | 58 | 61 | M | Bulky LAD | RCVP, Alemtuzumab | del17p, monosomy 14, monosomy 15 | 5.4 | 3.3 | 11.6 | 41 |
| ALL-1 | 66 | 67 | M | Relapsed disease | C, Mitoxantrone, vincristine, etoposide | Normal karyotype | 2.9 | 0.7 | 8.6 | 126 |
| ALL-2 | 45 | 48 | F | Relapsed disease | HyperCVAD, mitoxantrone, cytarabine, vincristine | Normal karyotype | * | * | * | * |
IgVH indicates immunoglobulin heavy chain; WBC, white blood cell; ALC, absolute lymphocyte count; Hgb, hemoglobin; PLT, platelet; LAD, lymphadenopathy; FCR, fludarabine, cyclophosphamide, rituximab; PCRM, pentostatin, cyclophosphamide, rituximab, mitoxantrone; FR, fludarabine, rituximab; RCVP, rituximab, cyclophosphamide, vincristine, prednisone; PCR, pentostatin, cyclophosphamide, rituximab; R, rituximab; CVP, cyclophosphamide, vincristine, prednisone; RC, rituximab, cyclophosphamide; C, cyclophosphamide; and HyperCVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone.
This patient is yet to be treated with modified T cells.